Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CS2009 monotherapy and combination therapy in advanced solid tumors
CTR20251926Phase 2Active
- Sponsor
- Shenshi Biotech
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS2009 in Nonhematologic neoplasms, sponsored by Shenshi Biotech. Started May 2025; status: active.
02
Drugs
CS2009
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251926.